Global Overactive Bladder Therapeutics Market 2014-2018

過活動膀胱(OAB)治療薬の世界市場:抗ムスカリン剤、ß3アドレナリン受容体作動薬

◆タイトル:Global Overactive Bladder Therapeutics Market 2014-2018
◆商品コード:IRTNTR4514
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年11月5日
◆ページ数:91
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥316,400見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"過活動膀胱(OAB)治療薬の世界市場:抗ムスカリン剤、ß3アドレナリン受容体作動薬"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、投与経路(ROA)別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Overactive Bladder
Overactive bladder is a urological condition associated with urination problems. The condition is characterized by bladder storage symptoms such as urgency, change in frequency of urination, nocturia, or urinary incontinence. It is also known as overactive bladder syndrome. Although it is not a life-threatening condition, it is often stigmatized and debilitating. Some of the important symptoms of overactive bladder are urinary urgency and incontinence. The pathophysiology of overactive bladder is not characterized completely. The symptoms of overactive bladder can last for a lifetime or it can relapse and remit. The problem can be resolved through treatment. Overactive bladder can affect a person irrespective of the gender. The reason is the abnormal contraction of the urinary detrusor muscle of the bladder. In addition, overactive bladder can be related to neurological diseases such as Parkinson’s disease and multiple sclerosis.

TechNavio’s analysts forecast the Global Overactive Bladder Therapeutics market to grow at a CAGR of 1.14 percent over the period 2013-2018.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Overactive Bladder Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of overactive bladder, which include:
• Anti-muscarinic Agent
• Beta-3-Adrenergic Receptor Agonist

TechNavio’s report, Global Overactive Bladder Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Overactive Bladder Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Actavis
• Allergan
• Astellas Pharma
• Pfizer

[Other Prominent Vendors]
• Addex Therapeutics
• AltheRx Pharmaceuticals
• American Oriental Bioengineering
• Antares Pharma
• Apogepha Arzneimittel
• Auxilium Pharmaceuticals
• Bayer
• elbion
• FemmePharma
• Ferring Pharmaceuticals
• GlaxoSmithKline
• Hisamitsu Pharmaceutical
• Hydra Biosciences
• Ion Channel Innovations
• Ipsen
• Janssen
• Kissei Pharma
• Kwang Dong Pharmaceutical
• KYORIN Pharma
• Laboratorios SALVAT
• LG Life Sciences
• Lipella Pharmaceuticals
• Merck
• Motif BioSciences
• Mylan
• Novartis
• Ono Pharmaceuticals
• Ranbaxy Laboratories
• Recordati
• Sanofi
• Sunovion
• Takeda Pharmaceutical
• TARIS BioMedical
• Teva Pharmaceutical
• TheraVida
• Toray Industries
• Urigen Pharmaceuticals

[Market Driver]
• Rise in Geriatric Population
• For a full, detailed list, view our report

[Market Challenge]
• Difficulty in Disease Diagnosis
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Enablex/Emselex
04.1.2 Gelnique
04.1.3 Oxytrol
04.1.4 Botox
04.1.5 Sanctura/ Sanctura XR
04.1.6 Myrbetriq
04.1.7 Vesicare
04.1.8 Detrol/Detrol LA
04.1.9 Toviaz
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Molecule Type
08.1 Biologics
08.2 Small Molecules
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
09.3 Topical
10. Market Segmentation by Class of drugs
10.1 Anti-muscarinic Agent
10.2 Beta-3-Adrenergic Receptor Agonist
11. Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
11.3 Semisolid
11.4 Transdermal
12. Rate of Incidence and Prevalence
13. Geographical Segmentation
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2013
21.2.1 Actavis
21.2.2 Allergan
21.2.3 Astellas Pharma
21.2.4 Pfizer
21.3 Other and Future Prominent Vendors
22. Pipeline Portfolio
23. Key Vendor Analysis
23.1 Actavis plc
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.2 Allergan Inc.
23.2.1 Key Facts
23.2.2 Business Description
23.2.3 Business Segmentation
23.2.4 Revenue by Business Segmentation
23.2.5 Revenue Comparison 2011-2013
23.2.6 Revenue by Geographical Segmentation
23.2.7 Business Strategy
23.2.8 Key Developments
23.2.9 SWOT Analysis
23.3 Astellas Pharma
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Product Segmentation
23.3.4 Product Segmentation by Revenue 2012 and 2013
23.3.5 Geographical Segmentation by Revenue 2013
23.3.6 Business Strategy
23.3.7 Recent Developments
23.3.8 SWOT Analysis
23.4 Pfizer
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Geographical Segmentation by Revenue
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
24. Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Global Overactive Bladder Therapeutics Market 2013-2018 (US$ billion)
Exhibit 3: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type
Exhibit 4: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type 2013
Exhibit 5: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration
Exhibit 6: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration 2013
Exhibit 7: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs
Exhibit 8: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs 2013
Exhibit 9: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form
Exhibit 10: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form 2013
Exhibit 11: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2013
Exhibit 12: Global Overactive Bladder Therapeutics Market Share Analysis 2013
Exhibit 13: Prescription chart
Exhibit 14: By drugs prescribed (up to 2011)
Exhibit 15: YoY Sales Comparison of Botox 2008-2013 (in US$ million)
Exhibit 16: YoY Sales Comparison of Vesicare 2008-2013 (in US$ million)
Exhibit 17: YoY Sales Comparison of Vesicare in Japan 2008-2013 (in US$ million)
Exhibit 18: YoY Sales Comparison of Vesicare in the Americas 2008-2013 (in US$ million)
Exhibit 19: YoY Sales Comparison of Vesicare in Europe 2008-2013 (in US$ million)
Exhibit 20: YoY Sales Comparison of Vesicare in Asia 2008-2013 (in US$ million)
Exhibit 21: Sales Comparison of Vesicare 2008-2013 (in US$ million)
Exhibit 22: YoY Sales Comparison of Detrol/Detrol LA 2009-2013 (in US$ million)
Exhibit 23: YoY Sales Comparison of Toviaz 2009-2013 (in US$ million)
Exhibit 24: Pipeline Molecules for the Treatment of Overactive Bladder
Exhibit 25: Global Overactive Bladder Therapeutics Market Business Segmentation 2013
Exhibit 26: Global Overactive Bladder Therapeutics Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 27: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 28: Allergan Inc.: Business Segmentation
Exhibit 29: Allergan Inc.: Revenue by Business Segmentation 2013
Exhibit 30: Allergan Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ billion)
Exhibit 31: Allergan Inc.: Revenue by Geographical Segmentation 2013
Exhibit 32: Astellas Pharma: Product Segmentation 2013
Exhibit 33: Astellas Pharma: Product Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: Astellas Pharma: Geographical Segmentation by Revenue 2013
Exhibit 35: Pfizer: Business Segmentation by Revenue 2013
Exhibit 36: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 37: Pfizer: Geographical Segmentation by Revenue 2013



【掲載企業】

Actavis, Allergan, Astellas Pharma, Pfizer, Addex Therapeutics, AltheRx Pharmaceuticals, American Oriental Bioengineering, Antares Pharma , Apogepha Arzneimittel , Auxilium Pharmaceuticals, Bayer, elbion, FemmePharma , Ferring Pharmaceuticals,GlaxoSmithKline, Hisamitsu Pharmaceutical, Hydra Biosciences, Ion Channel Innovations, Ipsen, Janssen, Kissei Pharma, Kwang Dong Pharmaceutical, KYORIN Pharma, Laboratorios SALVAT, LG Life Sciences , Lipella Pharmaceuticals, Merck,Motif BioSciences, Mylan, Novartis, Ono Pharmaceuticals, Ranbaxy Laboratories, Recordati, Sanofi, Sunovion, Takeda Pharmaceutical, TARIS BioMedical, Teva Pharmaceutical , TheraVida, Toray Industries , Urigen Pharmaceuticals

【資料のキーワード】

過活動膀胱(OAB)、治療、治療薬、抗ムスカリン剤、ß3アドレナリン受容体作動薬、製薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[過活動膀胱(OAB)治療薬の世界市場:抗ムスカリン剤、ß3アドレナリン受容体作動薬] (Global Overactive Bladder Therapeutics Market 2014-2018 / IRTNTR4514)販売に関する免責事項
[過活動膀胱(OAB)治療薬の世界市場:抗ムスカリン剤、ß3アドレナリン受容体作動薬] (Global Overactive Bladder Therapeutics Market 2014-2018 / IRTNTR4514)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆